home / stock / huma / huma news

HUMA News and Press, Humacyte Inc. From 08/03/23

Stock Information
Company Name: Humacyte Inc.
Stock Symbol: HUMA
Market: NASDAQ
Website: humacyte.com
Menu
HUMA HUMA Quote HUMA Short HUMA News HUMA Articles HUMA Message Board
Get HUMA Alerts

News, Short Squeeze, Breakout and More Instantly...
HUMA - Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel(TM) (HAV(TM))

Results published in Journal of Vascular Surgery – Vascular Science DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, a...
HUMA - ANNX, SILK and VIRT are among after hour movers

2023-07-28 17:39:07 ET Gainers: Annexon ( ANNX ) +5% . Fluence Energy ( FLNC ) +4% . Humacyte ( HUMA ) +3% . Stoke Therapeutics ( STOK ) +3% . Brightcove ( BCOV ) +3% . Losers: Silk Road Medical ( SILK ) -5% . ...

HUMA - Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(TM) (HAV(TM)) for Vascular Trauma Repair

-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology...

HUMA - Avrobio, Cardiff Oncology top healthcare gainers; Vaxart, Carisma among losers

2023-06-07 10:01:47 ET Gainers: Avrobio ( AVRO ) +10% . Cardiff Oncology ( CRDF ) +8% . IceCure Medical ( ICCM ) +7% . Humacyte ( HUMA ) +6% . TScan Therapeutics ( TCRX ) +4% . Losers: Vaxart ( VXRT ) -27% . Carism...
HUMA - Humacyte to Present at the Jefferies Healthcare Conference

DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founde...

HUMA - Humacyte Gets A Lifeline

2023-05-12 18:40:22 ET Summary Today, we put Humacyte, Inc. back into the spotlight for the first time since last October. This intriguing developmental concern closed on an important financing deal this week and got a nice shout out from an analyst firm. An investment analysi...

HUMA - Humacyte Inc. (HUMA) Q1 2023 Earnings Call Transcript

2023-05-12 11:27:02 ET Humacyte Inc. (HUMA) Q1 2023 Results Conference Call May 12, 2023 08:00 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - Founder, President, CEO and Director Dale Sander - CFO, Chief Corporate Development Officer ...
HUMA - Humacyte GAAP EPS of -$0.36 misses by $0.15

2023-05-12 07:07:31 ET Humacyte press release ( NASDAQ: HUMA ): Q1 GAAP EPS of -$0.36 misses by $0.15 . The Company reported cash, cash equivalents and short-term investments of $131.7 million as of March 31, 2023. Humacyte believes that its cash, cash equival...

HUMA - Humacyte First Quarter 2023 Financial Results and Business Update

- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients - - Conference call and live webcast at 8:00 a.m. ET tod...

HUMA - Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million

- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones, and $10 million equity option - - Proceeds to support planned development and commerci...
Previous 10 Next 10